Saturday 7 November 2026 Export PPBT’s income statement to Excel — free account

Purple Biotech Ltd. Sponsored ADR

PPBT Healthcare Biotechnology

EPS: +110.2%
Free cash flow: −62.1%

Quarter to June 2026, against a year earlier

1.28 0.03 +2.40%

Follow PPBT

Alert me

Market cap: $2.0M
P/E: 0.0×
Fwd P/E: −3.7×
Dividend yield: —
F-score: 2/9
Altman Z: 5.49
Beneish M: −1.78
Dividend safety: n/a

Overview

Insider Decisions last twelve months

Trades a month
	Jan 26			Apr 26			Jul 26			Oct 26
Buy	—	—	—	—	—	—	—	—	—	—	—	—
Sell	—	—	—	—	—	—	—	—	—	—	—	—

Insider Ownership 0.00%

Capital & Financial Ratios $m

Size

Market Cap 2.03

Revenue ttm —

Net income ttm (24.59)

Free cash flow ttm (7.76)

Net debt Q (6.10)

Valuation

P/E 0.00

Forward P/E (3.68)

Price / sales 0.00

Forward P/S Powerpack

Price / FCF 0.00

Price / book 0.11

Financial health

Current ratio Q 3.70

Debt / equity Q 0.00

Interest coverage Q (144.33)

Growth

Revenue growth Q —

Operating income growth Q −5.10%

EPS, this year +89.57%

EPS, next year A +82.37%

Revenue, next year A 0.00%

EPS, past 5 yrs —

EPS, next 5 yrs A +78.99%

Green and red mark values outside typical ranges; (Q) is the latest quarter, (A) analysts’ estimates. How we judge →

Valuation vs history

P/B against its own 10 years 4.70%

10-year low 10-year high

EV/FCF against its own 10 years 75.27%

10-year low 10-year high

Dividends

Yield: —
Annual rate: —
Payout ratio: —

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	15	9	10	6
Receivables	—	—	—	—
Inventory	—	—	—	—
Other	0	0	0	0
	16	9	10	7

	2023	2024	2025	Q'26
Payables	4	1	2	0
ST’ Debt	—	—	—	—
Other	3	1	4	0
	10	4	8	2

Compound Annual Growth %

	10y	5y	3y
Sales	—	—	120.45%
Cash Flow	0.00%	0.00%	0.00%
Earnings	0.00%	0.00%	0.00%
Book Value	0.24%	(34.44%)	(41.03%)

Earnings Trends EPS, adjusted, against the consensus

Jun 2026 Estimate −0.98 Actual 1.07

−22.99 −16.19 −9.39 −2.59 4.21

Sep 2025 Miss −0.30

Dec 2025 Miss −16.45

Mar 2026 Beat +3.71

Jun 2026 Beat +2.05

Sep 2026 — Nov 13

Earnings per share against the consensus, by quarter
Quarter	Estimate	Reported	Result
Sep 2025	−2.60	−2.90	Miss by 0.30
Dec 2025	−3.40	−19.85	Miss by 16.45
Mar 2026	−3.80	−0.09	Beat by 3.71
Jun 2026	−0.98	1.07	Beat by 2.05
Sep 2026	−2.88	—	Reports 13 November 2026

EPS $

	Mar	Jun	Sep	Dec	Year
’26	(0.09)	0.41	—	—	—
’25	(1.70)	(3.98)	(2.90)	(46.61)	(54.96)
’24	(28.00)	(18.00)	(3.90)	(2.60)	(49.90)
’23	(50.00)	(50.00)	(144.67)	—	(180.00)
’22	(82.00)	(40.00)	(54.00)	(66.00)	(240.00)
’21	(75.61)	(0.06)	(35.73)	(57.34)	(210.00)
’20	—	(0.18)	—	0.00	(488.00)

Fiscal quarters ending in the months shown.

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	—	—	—	—	—
’19	—	—	—	—	1
’18	—	—	—	—	1

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(3)	(3)	—	—	—
’25	(2)	(2)	(1)	(1)	(6)
’24	(5)	(4)	(3)	(2)	(14)
’23	(6)	(5)	(4)	(5)	(20)
’22	(5)	(4)	(4)	(4)	(17)
’21	(3)	(5)	(3)	(4)	(15)
’20	—	(5)	—	(12)	(14)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(3)	(3)	—	—	—
’25	(2)	(2)	(1)	(1)	(6)
’24	(5)	(4)	(3)	(2)	(14)
’23	(6)	(5)	(4)	(5)	(20)
’22	(5)	(4)	(4)	(4)	(17)
’21	(3)	(5)	(3)	(4)	(15)
’20	—	(5)	—	(12)	(14)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	TTM Jun ’26	Trend	10 yrs	2026e	2027e	2028e	Next 3/yr
													Ten-year view		Analyst estimates Powerpack
Income, $m
Income, $m	Revenue	—	0	1	1	—	—	—	—	—	—	—		+216.2%	8	—	—	—
	Gross margin, %	0.00	100.00	100.00	100.00	(23.50)	0.00	0.00	—	—	—	0.00		0.0 pt	Powerpack Purple Biotech Ltd. Sponsored ADR’s next three years, line by line See the consensus for every other line: earnings, margins, cash flow, valuation and returns. Unlock estimates Try Powerpack free for 7 days, then $99 / year ($8.25 a month). Cancel any time. Also in Powerpack: every quarter, Excel exports, API & MCP access. Compare plans
	EBT	(12)	(13)	(6)	(6)	(29)	(18)	(22)	(20)	(7)	(26)	(25)		+9.1%
	EBT margin, %	0.00	(12,913.00)	(556.90)	(567.70)	0.00	0.00	0.00	0.00	0.00	0.00	0.00		0.0 pt
	Net income	(12)	(13)	(6)	(6)	(29)	(18)	(22)	(20)	(7)	(26)	(25)		+9.1%
Per share, $
Per share, $	Revenue	0.00	21.28	140.85	103.09	0.00	0.00	0.00	0.00	0.00	0.00	0.00		n/m
	Earnings	(4,400.00)	(2,600.00)	(740.00)	(600.00)	(488.00)	(210.00)	(240.00)	(180.00)	(44.40)	(54.96)	(49.19)		(38.6%)
	Cash flow	(2,159.31)	(1,835.53)	(1,194.37)	(575.36)	(239.95)	(169.44)	(185.12)	(179.99)	(87.60)	(11.78)	(7.14)		(44.0%)
	Capex	(3.45)	(2.77)	(2.25)	(1.13)	(2.71)	(1.31)	(2.52)	(0.03)	0.00	(0.01)	(0.01)		(50.5%)
	Free cash flow	(2,162.76)	(1,838.30)	(1,196.62)	(576.49)	(242.66)	(170.75)	(187.64)	(180.02)	(87.60)	(11.79)	(7.15)		(44.0%)
	Book value	4,615.52	1,848.51	1,549.86	1,119.48	1,386.99	741.53	521.00	309.82	200.68	20.12	11.25		(45.3%)
	Shares, m	0	0	0	0	0	0	0	0	0	0	1		+76.4%
Valuation, ×
Valuation, ×	P/E	—	0.00	0.00	0.00	0.00	—	—	—	—	—	0.00		0.0
	P/S	—	0.00	0.00	0.00	0.00	—	—	—	—	—	0.00		0.0
	P/B	—	0.00	0.00	282.02	165.93	—	—	—	—	—	0.11		112.0
	EV/Sales	—	0.00	0.00	0.00	0.00	—	—	—	—	—	0.00		0.0
	EV/FCF	—	0.31	0.25	(153.97)	(529.55)	—	—	—	—	—	0.54		(170.7)
Cash, $m
Cash, $m	Operating cash flow	(6)	(9)	(8)	(6)	(14)	(15)	(17)	(20)	(14)	(6)	(8)		(1.1%)
	Capex	0	0	0	0	0	0	0	0	—	0	0		(12.5%)
	Free cash flow	(6)	(9)	(8)	(6)	(14)	(15)	(17)	(20)	(14)	(6)	(8)		(1.1%)
Balance, $m
Balance, $m	Working capital	14	4	5	5	56	44	26	6	5	2	5		(18.7%)
	Net debt	(15)	(7)	(7)	(6)	(58)	(47)	(32)	(15)	(9)	(10)	(6)		(4.6%)
	Shareholders’ equity	13	9	11	11	80	65	47	34	33	10	12		(3.6%)
Returns, %
Returns, %	ROA	(94.26)	(83.70)	(35.98)	(39.74)	(56.84)	(23.88)	(34.72)	(40.19)	(17.80)	(96.63)	(100.91)		(2.4) pt
	ROIC	0.00	(596.87)	(113.22)	(100.19)	(37.70)	(62.60)	(94.27)	(73.71)	(28.20)	(20,189.71)	(290.25)		(20,189.7) pt
	ROE	(106.29)	(110.33)	(52.81)	(53.52)	(61.80)	(25.38)	(38.62)	(48.85)	(21.55)	(123.97)	(110.67)		(17.7) pt
People
People	Employees	9	1	10	9	13	19	20	20	9	10	—		+1.2%
	Revenue/emp, $m	0.00	0.10	0.10	0.11	0.00	0.00	0.00	0.00	0.00	0.00	—		n/m

Negative figures in brackets.

estimates

All 10 years →

Fiscal years to Dec 2019 · fundamentals updated 26 Oct 2026

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
HCWB HCW Biologics Inc.	$2.3M	— (loss-making)	— (loss-making)	+1,954.55% (above 0%: growing)	n/m	−20.84% (below 0%: shrinking)	(69.25%)	(2,335.03%)	Compare
APVO Aptevo Therapeutics Inc.	$2.3M	— (loss-making)	— (loss-making)	+28.62% (above 0%: growing)	n/m	+23.11% (above 0%: growing)	0.00%	0.00%	Compare
SLXN Silexion Therapeutics Corp	$2.2M	— (loss-making)	—	—	n/m	−16.63% (below 0%: shrinking)	—	0.00%	Compare
BRTX Biorestorative Therapies, Inc.	$2.1M	— (loss-making)	— (loss-making)	−7.20% (below 0%: shrinking)	n/m	−35.26% (below 0%: shrinking)	68.10%	(14,593.53%)	Compare
SILO Silo Pharma, Inc.	$2.1M	— (loss-making)	18.4×	0.00%	n/m	+39.17% (above 0%: growing)	(15.00%)	0.00%	Compare
PPBT Purple Biotech Ltd. Sponsored ADR	$2.0M	— (loss-making)	— (loss-making)	—	n/m	−62.10% (below 0%: shrinking)	0.00%	0.00%
REVB Revelation Biosciences, Inc.	$2.0M	— (loss-making)	—	—	n/m	−35.29% (below 0%: shrinking)	0.00%	0.00%	Compare
ENLV Enlivex Ltd.	$2.0M	0.0×	—	—	n/m	+35.94% (above 0%: growing)	0.00%	0.00%	Compare
EDVA Splash Beverage Group, Inc.	$1.9M	— (loss-making)	— (loss-making)	−99.57% (below 0%: shrinking)	n/m	−95.72% (below 0%: shrinking)	42.86%	0.00%	Compare
Median of peers	$2.1M	—	—	0.00%	—	−18.74%	0.00%	0.00%

All 621 Biotechnology stocks →

Purple Biotech Ltd. Sponsored ADR (PPBT) Latest News

29 Oct

Impact 4 · 9:00 AM · GlobeNewswire

Purple Biotech Announces IM1240 Abstract Selected for Oral Presentation at the 38th EORTC-NCI-AACR Symposium

Impact 4 · 7:33 AM · GlobeNewswire

Purple Biotech Achieves Manufacturing Milestone for IM1240, a Tri-Specific Antibody from the CAPTN-3 Platform

2 Sep

Impact 3 · 11:07 AM · InvestorsHub

Purple Biotech U.S. Patent Allowance Strengthens CAPTN-3 Multispecific Antibody Protection

Impact 3 · 7:30 AM

New U.S. Patent Allowance Strengthens Protection for CAPTN-3 Modular Platform for Next-Generation Multispecific Antibodies

15 May

Impact 3 · 7:00 AM · GlobeNewswire

Purple Biotech Reports First Quarter 2026 Financial Results and Business Highlights

27 Apr

Impact 4 · 7:00 AM · GlobeNewswire

Purple Biotech Announces New Data from CAPTN-3 Platform Tri-specific IM1240

23 Apr

Impact 3 · 7:00 AM · GlobeNewswire

Purple Biotech Establishes Scientific Advisory Board to Support Development of CAPTN-3 Tri-Specific Antibody Platform

25 Mar

Impact 4 · 8:00 AM · GlobeNewswire

Purple Biotech Announces AI Collaboration with Converge Bio to Accelerate Development of its Next-Generation Tri-Specific Antibody Platform

17 Mar

Impact 4 · 7:00 AM · GlobeNewswire

Purple Biotech Regains Compliance with Nasdaq

13 Mar

Impact 4 · 8:04 AM · GlobeNewswire

Purple Biotech Announces CEO Transition

Impact 3 · 8:00 AM · GlobeNewswire

Purple Biotech Reports Fourth Quarter and Full Year 2025 Financial Results

7 Jan

Impact 4 · 8:00 AM · GlobeNewswire

Purple Biotech Achieves Toxicology Milestone Demonstrating an Expanded Therapeutic Window for CAPTN-3 Platform Tri-specific Antibody, IM1240

11 Dec

Impact 4 · 7:00 AM · GlobeNewswire

Purple Biotech Reports Positive New Preclinical Data Demonstrating Multi-Arm Anti-Tumor Activity Across Two CAPTN-3 Tri-Specific Antibodies at ESMO Immuno-Oncology Congress 2025

4 Dec

Impact 4 · 7:00 AM

Purple Biotech to Present New Preclinical Data from its CAPTN-3 Tri-Specific Antibody Platform at the European Society of Medical Oncology Immuno-Oncology (ESMO-IO) 2025 Annual Congress

14 Nov

Impact 3 · 8:00 AM · GlobeNewswireMotley FoolGuruFocus.comGuruFocus.comZacksGuruFocus.comAssociated Press Finance

Purple Biotech Reports Third Quarter 2025 Financial Results and Provides Business Update

10 Sep

Impact 4 · 8:00 AM

Purple Biotech Receives Intention to Grant a European Patent Covering NT219 Combinations with Immunotherapies or MEK Inhibitors to Overcome Tumor Resistance

5 Sep

Impact 3 · 4:00 PM · GlobeNewswire

Purple Biotech Announces Closing of Up To $18 Million Public Offering $6 million upfront with up to an additional $12 million of potential aggregate gross proceeds upon the exercise in full of short-term warrants

4 Sep

Impact 4 · 7:00 AM · GlobeNewswire

Purple Biotech Announces New Data Supporting the Unique Design of CAPTN-3 Tri-Specific Antibody IM1240 in Collaboration with the Icahn School of Medicine at Mount Sinai

Impact 3 · 9:15 AM

Purple Biotech Announces Pricing of Up To $18 Million Public Offering

3 Sep

Impact 4 · 7:00 AM · GlobeNewswire

Purple Biotech Expands CAPTN-3 Portfolio with IM1305, a Novel Tri-Specific Antibody Targeting TROP2

6 Aug

Impact 3 · 7:00 AM · GlobeNewswire

Purple Biotech Reports Second Quarter 2025 Financial Results

23 Jul

Impact 4 · 7:00 AM · GlobeNewswire

Purple Biotech CEO Issues Letter to Shareholders Highlighting Pipeline Progress and Clinical Milestones Achieved in First Half of 2025

23 Jun

Impact 4 · 7:00 AM · GlobeNewswire

Purple Biotech Highlights Significant Advantages of the Novel CAPTN-3 Tri-Specific Antibody Platform at the EACR 2025 Annual Congress

17 Jun

Impact 4 · 7:00 AM

Purple Biotech Announces Initiation of Phase 2 Study of NT219 in Patients with Head and Neck Cancer

4 Jun

Impact 4 · 7:00 AM

Purple Biotech Announces Poster Presentation at EACR 2025 on its Novel CAPTN-3 Tri-Specific Antibody Platform

21 May

Impact 4 · 7:10 AM · GlobeNewswire

Purple Biotech Reports First Quarter 2025 Financial Results

12 May

Impact 4 · 7:30 AM · GlobeNewswire

Purple Biotech Appoints Shai Lankry as Chief Financial Officer

30 Apr

Impact 4 · 7:00 AM · GlobeNewswire

Purple Biotech Reports Final Data from Phase 2 Study of CM24 in Pancreatic Cancer Patients at AACR 2025 Annual Meeting: Improved Outcomes and Significant Efficacy in Biomarker-Enriched Subgroups

28 Apr

Impact 4 · 8:28 AM

Purple Biotech Reports Positive NT219 Data at AACR for Colorectal and Head and Neck Cancers

16 Apr

Impact 4 · 7:00 AM

Purple Biotech Announces Publication in the Neuro Oncology Journal Demonstrating the Potential of NT219 to Suppress Brain Metastasis of Colorectal Cancer

Insider Decisions last twelve months

Capital & Financial Ratios $m

Valuation vs history

Dividends

Assets vs Liabilities $m

Compound Annual Growth %

Earnings Trends EPS, adjusted, against the consensus

EPS $

Revenue $m

Operating Cash Flow $m

Free Cash Flow $m

Target Price Range

Recommendation Rating

Ten years at a glance Fiscal years to December

Purple Biotech Ltd. Sponsored ADR vs peers in Biotechnology (Q) = latest quarter vs a year earlier

Purple Biotech Ltd. Sponsored ADR (PPBT) Latest News

29 Oct

2 Sep

15 May

27 Apr

23 Apr

25 Mar

17 Mar

13 Mar

7 Jan

11 Dec

4 Dec

14 Nov

10 Sep

5 Sep

4 Sep

3 Sep

6 Aug

23 Jul

23 Jun

17 Jun

4 Jun

21 May

12 May

30 Apr

28 Apr

16 Apr

Stockrow Weekly